Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Subscribe To Our Newsletter
Global Fund Pushes for More Rapid Scale-Up in Indonesia’s TB Grants
GFO

Global Fund Pushes for More Rapid Scale-Up in Indonesia’s TB Grants

Author:

Download PDF The objective of the second phase of two TB grants to Indonesia is to ensure early and full access to the most appropriate diagnosis and treatment services in both the public and private health sectors for everyone suffering from TB. As reported in a previous GFO article, Indonesia was awarded renewal funding of up to $36.3 million by…

Article Type:

Article Number:

ABSTRACT New and renewal funding of $37.5 million for two TB grants to Indonesia will be used to help ensure early and full access to the most appropriate diagnosis and treatment services. Technical assistance from partners is being provided to allow for a more rapid scale-up of services than Indonesia had originally planned.

The objective of the second phase of two TB grants to Indonesia is to ensure early and full access to the most appropriate diagnosis and treatment services in both the public and private health sectors for everyone suffering from TB.

As reported in a previous GFO article, Indonesia was awarded renewal funding of up to $36.3 million by the Global Fund to Fight AIDS, Tuberculosis and Malaria for two TB grants: IND-T-MOH ($29.7 million), for which the principal recipient (PR) is the Ministry of Health; and IND-809-G10-T ($6.6 million), for which the PR is the Central Board of Aisyiyah. Indonesia was also awarded $1.2 million in new funding model (NFM) interim applicant funding for the Aisyiyah grant.

When it reviewed the funding requests, the Grant Approvals Committee (GAC) emphasised the need to scale up coverage of TB/HIV and multiple-drug-resistant TB (MDR-TB). The GAC said that it acknowledged the country’s preference for a gradual approach, as expressed in the request for continued funding. The GAC also acknowledged concerns expressed by the MOH in relation to increasing absorption, and the need to balance rapid scale-up with strengthening financial management systems and programme quality. (Up to the end of Semester 3 of Phase 1, the MOH had absorbed only 50% of the cumulative budget.)

However, the GAC noted that significant investments in technical assistance are being made by partner organisations to complement Global Fund resources. These include support to NGOs to pilot models of care, as well as investments in improving MDR-TB programme quality, and financial management capacity. The GAC added that if the TB programme were able to achieve scale-up and demonstrate an ability to increase absorption, Indonesia would be well placed to apply for additional resources under the NFM.

The GAC noted that the Phase 2 budget does not include any money for first-line drugs (FLD) and said that it expects that Indonesia will continue its full financing of national FLD requirements.

Information for this article was taken from Board Decisions GF-B29-EDP3 and GF-B29-EDP4, and from B29-ER-02, the Report of Secretariat Funding Recommendations for July 2013. These documents are not available on the Global Fund website.

Tags :

Leave a reply

  • Anonymous comments (0)
  • Facebook Comments

Your email address will not be published.

Aidspan

Categories*

Loading
Aidspan

Categories*

Loading